Dolutegravir/rilpivirine (DTG/RPV) (Juluca) is an oral single-tablet regimen indicated for the treatment of HIV-1 infection in adults who are virologically suppressed (HIV ribonucleic acid [RNA] < 50 copies/mL). It contains: dolutegravir, an integrase stand transfer inhibitor (INSTI); and rilpivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI). DTG/RPV is available as a fixed-dose combination (50 mg/25 mg) tablet and is taken once daily. At the manufacturer-submitted unit price of $34.87 per tablet, the annual cost of treatment is approximately $12,728 per patient. The manufacturer is seeking reimbursement in accordance with the Health Canada indication.